Ged buys the 51% from Andalusian company Vitro to help it expand internationally in the market for in vitro diagnostic products and laboratory software.
Corporate finance analysis Vitro
Vitro is a Sevillian company, with almost 30 years of experience, founded by two former directors of Abbott. The company is dedicated to distribute and manufacture products for the diagnosis of diseases, such as high quality reagents and software for hospital laboratories. Years later, GED was reinforced with Master Diagnstica, Máster Diagnóstica, a leading company in the diagnostic sector in Granada.
Vitro has moved from distributing third-party products to creating its own solutions, thus making a major leap forward in the value chain. The company has an R&D&I department that carries out the manufacture of kits and development projects for new reagents. It also has a team of in-house programmers who develop the software integrated in Vitro's products. The company also participates with the University of Seville (Fidetia) in the production of robotic components for its own manufacturing equipment.
In 2016 it achieved a turnover of €15,5M thanks to its positioning in anatomical pathology, biochemistry, microbiology and immunology laboratories in public and private hospitals and research centres. Today, the company exports the 15% of its sales to more than 30 countries, an increase of 50% over the previous year.
On GED's takeover
Ged has bought the company's 51% in order to boost the group's international growth, both organically and inorganically.
The company wants to grow in the international market, where it is growing at a rate of 50% per year, and is therefore planning to realise mergers and acquisitions in Latin America.
Enrique Centelles Satrustegui, Managing Partner of GED V España FCR, who is leading the deal, says: "Vitro is an investment with significant development potential and fits our criteria and objectives for this fund, the construction of a growth project in Spain and in international markets. The healthcare sector, and in particular the in vitro diagnostics segment, has recovered significantly in recent years.
Ged, a very active fund
This is the fund's fifth investment through its fifth private equity vehicle, with a target size of 150 million. The first dates back to last summer, when it acquired Discefa (specialising in the frozen octopus business). It then bought Araven (design, manufacture and marketing of shopping trolley products) and then Cubers (manufacture of yarn cubes). The last one, a month ago, was Gestión Tributaria Territorial (GTT) (design of information systems on issues related to local tax management).
Other posts that may interest you
If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.
